PDSB
PDS Biotechnology CorpPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 15 ▲ PDS Biotechnology announced preliminary data from a trial using its…
- Jul 22 ▼ PDS Biotechnology Corp's $200M shelf registration (S-3) became effec…
- Aug 11 ▼ PDS Biotechnology announced a strategic refocus prioritizing PDS0301…
- Aug 13 ▼ PDS Biotech reported Q2 2026 EPS of -$0.18, a 42.1% miss vs consensu…
- Sep 4 ▼ PDS Biotechnology amended its $6M promissory note with YA II PN, Ltd…
- Sep 15 ▼ Short interest jumps 172.7% to 6.41M
- Sep 22 FDA: PDS Biotech Announces Publication of VERSATILE-002 Phase 2…
- Sep 22 ▲ PDS Biotech announced the publication of Phase 2 VERSATILE-002 trial…
- Sep 22 ▲ Nant Capital LLC, controlled by Dr. Patrick Soon-Shiong, filed a Sch…
- Sep 22 ▲ PDS Biotech published Phase 2 VERSATILE-002 results in JAMA Oncology…
- Sep 30 ▲ Short interest falls 56.8% to 2.77M
- Oct 14 ▼ PDS Biotech filed an S-3 shelf registration to register up to 110,00…
- Nov 13 New catalyst: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsBULLISH
Q3 2026: 8 added (0 new), 2 trimmed or exited.
- AnalystsBULLISH
8 of 9 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate −$0.090 → −$0.070 over 90 days. 1 up, 0 down in 30 days.
- Short sellersSTEADY
Short interest +4.0% to 3.52M shares. 1.0 days to cover, ≈3.4% of shares.
- TrendDOWNTREND
8% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 7.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | $466.4K |
| JANE STREET GROUP, LLC | ADD | $383.5K |
| UBS Group AG | DOUBLED | $176.9K |
| COMMONWEALTH EQUITY SERVICES, LLC | ADD | $88.6K |
| GROUP ONE TRADING LLC | DOUBLED | $81.9K |
| JPMORGAN CHASE & CO | DOUBLED | $37.1K |
| OSAIC HOLDINGS, INC. | ADD | $33.8K |
| MORGAN STANLEY | NEAR_EXIT | $18.6K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
9 analystsPrice is below the lowest target. Median implies +387%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 29, 2026 | B. Riley Securities REITERATE | Buy |
| Sep 8, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Aug 26, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Aug 13, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Wendel Bruce Director Oct 18, 2026 | AWARD | 22,700 sh |
Ramsdell Deborah Director Oct 18, 2026 | AWARD | 22,700 sh |
Dawson John Andrew Director Oct 18, 2026 | AWARD | 22,700 sh |
Brown Spencer D. Senior VP, General Counsel Jan 12, 2026 | AWARD | 300,000 sh |
Freitag Gregory Gene Director Jan 12, 2026 | AWARD | 54,876 sh |
CONN GREGORY Chief Scientific Officer Jan 12, 2026 | AWARD | 150,000 sh |
Toutain Stephan Chief Operating Officer Jan 12, 2026 | AWARD | 300,000 sh |
Shepard Kirk V. Chief Medical Officer Jan 12, 2026 | AWARD | 300,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.07 | -$0.07–-$0.07 | +22.2% | $0.00 |
| Next Q | None | None | No data | $0.00 |
| Current FY | -$0.44 | -$0.44–-$0.44 | +10.2% | $0.00 |
| Next FY | -$0.13 | -$0.18–-$0.08 | +62.3% | $9.4M |
Short side
FINRA· Oct 30, 2026SecBot reports
24 filings · 4 press releases · 5 bullish · 7 bearish · 12 neutral- NEUTRAL PRESS-RELEASENov 13, 2026
PDS Biotech reported Q3 2026 net loss of $0.11 per share, narrower than the $0.19 loss a year ago…
The PIPE closing and warrant exercise by Nant Capital provide near-term liquidity but increase share count. The $10M milestone tied to a Phase 3 protocol submission for PDS0301 is pending and could…
- NEUTRAL SC 13D/ANov 12, 2026
Nant Capital exercised its 17,699,115 Common Warrants in full, converting them into 9,851,119…
The warrant exercise is a procedural step that does not change the activist's economic exposure or strategic position. Watch for the Phase 3 protocol submission for PDS0301, which would trigger the…
- NEUTRAL 8-KNov 10, 2026
PDS Biotechnology announced that NantWorks exercised warrants for 17,699,115 shares at $0.22 per…
The warrant exercise provides near-term cash but adds roughly 17.7 million shares to the float, diluting existing holders. Monitor the company's cash runway and progress toward the PDS0301 Phase 3…
- NEUTRAL 3Oct 20, 2026
Bruce Wendel filed a Form 3 initial statement of beneficial ownership with PDS Biotechnology Corp…
Monitor for subsequent Form 4 filings from Bruce Wendel to see if any open-market purchases or option exercises occur, which would signal insider conviction. For now, this is a routine…
All PDSB filing & press-release reports (28)
- PRESS-RELEASE reportNov 13, 2026
- SC 13D/A reportNov 12, 2026
- 8-K reportNov 10, 2026
- 3 reportOct 20, 2026
- 8-K reportOct 20, 2026
- 8-K reportOct 20, 2026
- S-3 reportOct 14, 2026
- 8-K reportOct 6, 2026
- 8-K reportSep 22, 2026
- PRESS-RELEASE reportSep 22, 2026
- SC 13D reportSep 21, 2026
- 8-K reportSep 4, 2026
- 8-K reportAug 19, 2026
- 8-K reportAug 13, 2026
- 8-K reportAug 11, 2026
- EFFECT reportJul 22, 2026
- DEFA14A reportJun 26, 2026
- 8-K reportJun 15, 2026
- 8-K reportJun 15, 2026
- 8-K reportJun 2, 2026
- PRESS-RELEASE reportMay 13, 2026
- 8-K reportMay 1, 2026
- S-3/A reportApr 27, 2026
- 8-K reportApr 24, 2026
- 8-K reportApr 15, 2026
- PRESS-RELEASE reportApr 15, 2026
- PRESS-RELEASE reportMar 30, 2026
- PRESS-RELEASE reportMar 24, 2026